For its second fiscal quarter (ending June 30), Bristol-Myers Squibb Co (NYSE: BMY) has reported E.P.S. of $0.83 compared to $0.99 a year ago. For the latest four quarters through June 30, E.P.S. were $-3.24 compared to $3.78 a year ago.
Recent Price Action
Bristol-Myers Squibb Co (NYSE: BMY) stock closed at $50.45 on 7/26/24 after a major increase of 11.4%. Moreover, this advance was accompanied by exceptionally high trading volume at 222% of normal. The stock has risen 19.0% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, BMY is expected to continue to be a major Value Builder.
Bristol-Myers Squibb has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Bristol-Myers Squibb has a neutral Appreciation Score of 57 but a poor Power Rating of 20, and the Negative Value Trend Rating results.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment